La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Monopar Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Monopar Therapeutics..

Monopar Therapeutics (NASDAQ:MNPR) Azioni, Catena delle Opzioni

Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Monopar Therapeutics Inc

News

AIFU

AIX Says Ning Li Has Been Appointed As Co-chief Executive Officer And Executive Director Of The Board, Effective Immediately

Telsey Advisory Group analyst Dana Telsey maintains Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) with a Market Perform and maintains $26 price target.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Market Perform on Gap, Maintains $26 Price Target

PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) disclosed a deal to acquire the remaining 50% stake in Sabra Dipping Company, LLC, and PepsiCo-Strauss Fresh Dips &amp; Spreads International GmbH<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42132599/pepsico-to-acquire-full-ownership-of-sabra-and-obela" rel="noreferrer noopener"> for an undisclosed amount</a>.
This acquisition will make PepsiCo the sole owner of the companies behind Sabra and Obela products.
Sabra and Obela, 50/50 joint ventures between PepsiCo and Strauss Group, focus on refrigerated dips and spreads.
PepsiCo, active in the fresh dips market for over 15 years, helped establish Sabra and Obela, with Sabra now leading the U.S. hummus market with $400 million in retail sales.
This acquisition supports PepsiCo&#8217;s goal to innovate and meet rising consumer demand for healthier options.
The transactions, pending customary closing conditions, are expected to finalize by the end of 2024.
Steven Williams, Chief Executive Officer, PepsiCo Foods North America, said, &#8221;As we evolve our food portfolio and bring people more choices for more occasions, our aim is to meet the growing demand for positive choices and on-the-go options.&#8221;
&#8220;Nutritious, simple foods like refrigerated dips and spreads represent a space we have long desired to expand in the U.S. and&nbsp;Canada. We are grateful to the Strauss Group for our long and successful partnership and look forward to this next chapter for the Sabra and Obela brands, as well as the PepsiCo food portfolio.&#8221;
As of September 7, PepsiCo&#8217;s cash and equivalents <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41225048/pepsico-adjusts-2024-revenue-expectations-after-mixed-q3-performance-and-global-challenges" rel="noreferrer noopener">stood at $7.3 billion</a>.
Price Action: PEP shares are up 0.07% at $160.46 premarket at the last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42111285/jim-cramer-says-this-food-and-beverage-manufacturer-goes-lower-its-just-become-just-too-darn-hard" target="_blank" rel="noreferrer noopener">Jim Cramer Predicts Pepsi Goes Lower: &#8216;It&#8217;s Just Become Too Darn Hard&#8217;</a></li>
</ul>

Equities

Large Cap

PepsiCo Strengthens Hold On US Hummus Market with Sabra & Obela Buyout

<a href="https://ec.europa.eu/commission/presscorner/detail/en/mex_24_6024" title="https://ec.europa.eu/commission/presscorner/detail/en/mex_24_6024">https://ec.europa.eu/commission/presscorner/detail/en/mex_24_6024</a>

Legal

Tech

AAPL

European Commission Closed Antitrust Investigation Into Apple's Rules For Developers Of e-Book/Audiobook Apps

Gap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) shares soared by 14.02% on Friday during pre-market hours, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, following the release of its third-quarter earnings report after Thursday&#8217;s market close. The retailer exceeded Wall Street expectations, leading to a positive revision in its annual sales outlook.
The <a href="https://www.benzinga.com/news/earnings/24/11/42125007/gap-stock-soars-on-better-than-expected-q3-results-raised-fy-guidance-details">company reported earning</a>s of 72 cents per share, surpassing the analyst consensus of 57 cents. Revenue for the quarter reached $3.82 billion, slightly above the anticipated $3.81 billion and marking an increase from last year&#8217;s $3.76 billion for the same period.
See Also: <a href="https://www.benzinga.com/24/11/42053687/peter-schiff-pokes-fun-at-microstrategys-bitcoin-buying-spree-michael-saylor-is-gonna-need-a-bigger-plan?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Peter Schiff Pokes Fun Of MicroStrategy&#8217;s Bitcoin Purchase: &#8216;Michael Saylor Is Gonna Need A Bigger Plan&#8217;</a>
Net sales rose by 2% compared to the previous year, with comparable sales increasing by 1%. The operating margin improved to 9.3%, up 270 basis points from the prior year.
Looking ahead, Gap has adjusted its full-year projections, now expecting net sales to rise between 1.5% and 2%. The company also anticipates a&nbsp;gross margin growth of 220&nbsp;basis points and an operating income margin in the mid-to-high 60% range. This optimistic outlook has contributed to the stock&#8217;s recent rally.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42102769/floki-beats-dogecoin-shiba-inu-with-double-digit-gains-after-coinbase-listing-announcement?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Floki Beats Dogecoin, Shiba Inu With Double-Digit Gains After Coinbase Listing Announcement</a></li>
</ul>
Image by Raysonho via Wikimedia Commons

Pre-Market Outlook

Markets

General

GAP Stock Surges 14% In Friday Pre-Market After Boosting Sales Forecast

Needham analyst Matt Dezort reiterates Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) with a Hold.

Reiteration

FTNT

Needham Reiterates Hold on Fortinet

As the U.S. dollar scaled a fresh 52-week high on Friday morning at 108.071 level, former Goldman Sachs FX strategist and senior fellow at Brookings Institution, Robin Brooks said in an X (formerly Twitter) post that, &#8220;Markets initially got this wrong, driving stocks up sharply right after Nov. 5.&#8221;
He added that &#8220;the prospect of tariffs isn&#8217;t obviously good for equities, while it&#8217;s clearly good for the Dollar. More Dollar strength is coming.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The Dollar (lhs) is now clearly outperforming S&amp;P 500 (rhs). Markets initially got this wrong, driving stocks up sharply right after Nov. 5. But the prospect of tariffs isn&#39;t obviously good for equities, while it&#39;s clearly good for the Dollar. More Dollar strength is coming&#8230; <a href="https://t.co/GEZr0IaDh8">pic.twitter.com/GEZr0IaDh8</a>
&mdash; Robin Brooks (@robin_j_brooks) <a href="https://twitter.com/robin_j_brooks/status/1859894280149717359?ref_src=twsrc%5Etfw">November 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Also read: <a href="https://www.benzinga.com/24/11/42088394/economist-gordon-johnson-slams-federal-reserve-for-asset-owner-centric-policies-says-fed-needs-to-focus-on-the-real-economy-over-stock-markets" target="_blank" rel="noreferrer noopener">Gordon Johnson Slams Federal Reserve For Asset-Owner Centric Policies, Says Jerome Powell Needs To Focus On ‘Real Economy': ‘…The Stock Market Will Be Fine'</a>
What Happened: A chart shared by Brooks compared the S&amp;P 500 Index and the Dollar Index during President-elect Donald Trump&#8217;s victory in 2016 and 2024. Measuring the performance of both indices from the day of the election on Nov. 5, the Dollar Index has risen by approximately 3.5%, outperforming the S&amp;P 500 Index, which advanced 2.9%.
Why It Matters: An <a href="https://www.benzinga.com/24/11/41939162/us-treasuries-edge-up-as-trumps-proposed-policies-possible-rate-cut-may-rekindle-inflation-fears-all-eyes-on-federal-reserves-next-steps">increase in tariffs</a> reduces the demand for imported goods and lifts domestic prices above the free trade price, gradually stoking inflation. This results in monetary tightening affecting the equities in the long run.
However, higher tariffs are positive for the domestic currency as its supply decreases and more money flows into the economy.
What Are Other Analysts Saying: Now that the Dollar Index has surpassed its previous 52-week high of 107.07, &#8220;a break of it may let <a href="https://www.benzinga.com/24/11/42103600/us-dollar-may-test-10860-level-as-geopolitical-tensions-cautious-fed-rhetoric-and-solid-us-economic-data-may-push-the-greenback-higher-says-expert">it test 108.60 </a>while 105.10 acting as a support,&#8221; said Kunal Sodhani, vice president of the global trading center at Shinhan Bank.
According to him, &#8220;the ongoing geopolitical tensions in the Middle East combined with the strong U.S. economic data and the Federal Reserve's cautious rhetoric on interest rate cuts, may push the U.S. Dollar to new highs&#8221;
As of Friday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) had gained 25.60% year-to-date, while the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) saw a 25.43% increase, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. Despite these strong returns, both ETFs were slightly down in pre-market trading on Friday.
Meanwhile, the <a href="https://www.benzinga.com/24/11/42133364/us-stocks-on-edge-but-likely-to-end-the-week-in-the-green-trumps-treasury-pick-in-focus-expert-says-case-for-fed-pause-in-december-getting-stronger">futures show a decline across major indices</a>: Nasdaq 100 down 0.51%, S&amp;P 500 down 0.40%, Dow Jones down 0.29%, and R2K down 0.08%.
Read next: <a href="https://www.benzinga.com/24/11/42103600/us-dollar-may-test-10860-level-as-geopolitical-tensions-cautious-fed-rhetoric-and-solid-us-economic-data-may-push-the-greenback-higher-says-expert">Dollar Upside On The Cards Amid Geopolitical Tensions, Cautious Fed And Solid US Economic Data, Says Expert</a>
Image via Wikimedia Commons

Macro Economic Events

Forex

Economics

Markets Misread Trump Win, Says Ex-Goldman Sachs Analyst: 'Prospects Of Tariffs Not Good For Equities'

Needham analyst Laura Martin downgrades Innovid (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTV#NYSE">CTV</a>) from Buy to Hold and maintains the price target from $3 to $3.

Downgrades

Needham Downgrades Innovid to Hold, Maintains Price Target to $3

Financial guidance and long-term targets The macro and microeconomic environment in which Global Blue operates remains highly favorable. The travel industry is experiencing positive trends, particularly in the high-end segment, and Global Blue has made significant progress in implementing strategic initiatives to further penetrate the market. In parallel, Global Blue has continued to outperform in the luxury market, driven by its unique exposure to affluent and high-net-worth international shoppers. That said, considering the recent luxury market slowdown and taking into account the Group's decision to accelerate €5 million of investments (fixed costs) in future growth initiatives (expansion into new countries, adaptation of Japan's business model and Hospitality Gateway), we have adapted our FY24/25 Adjusted EBITDA guidance to €185 million - $205 million.
Long-term targets include 8-12% revenue growth, &gt;50% drop-through, and a net leverage ratio of &lt;2.5x.

Guidance

Global Blue Expects FY24/25 Adj EBITDA Of €185M-€205M (Prior More Than €200M)

Needham analyst Mike Cikos reiterates N-able (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NABL#NYSE">NABL</a>) with a Buy and maintains $16.5 price target.

NABL

Needham Reiterates Buy on N-able, Maintains $16.5 Price Target

Earnings

Earnings Beats

Global Blue Gr Holding Q2 Sales €132.000M Beat €131.250M Estimate

Ahead of the potential market correction,&nbsp;Brian Arcese&nbsp;from&nbsp;Foord Asset Management&nbsp;has highlighted concerns over the U.S. economic growth and corporate earnings. These factors could trigger a correction if they continue to slow down.
What Happened: Arcese warned that a market correction could occur if U.S. GDP or earnings growth slows. Arcese noted that the S&amp;P 500 has&nbsp;been &#8220;expensive for quite a&nbsp;while,&#8221; with a price-to-earnings ratio exceeding 27, CNBC <a href="https://www.cnbc.com/2024/11/22/sp-correction-could-happen-if-gdp-or-earnings-growth-slows-says-asset-manager.html">reported</a>&nbsp;on Friday.
"We do think that a correction would be healthy, but you will need some type of catalyst for that correction to take place,&#8221; he said, highlighting two potential catalysts for a correction: slowing economic growth and inflation increases. 
U.S. GDP growth was less than anticipated in the third quarter, and&nbsp;inflation rose to 2.6% in&nbsp;October, as per recent data. He emphasized that high corporate earnings expectations, particularly outside IT and communication services, could also trigger a correction if growth slows.
See Also:&nbsp;<a href="https://www.benzinga.com/24/11/42079585/meta-google-and-microsoft-bet-big-on-ai-with-skyrocketing-capex-budgets-but-jensen-huangs-nvidia-poised-to-be-the-biggest-winner-says-analyst-only-game-in-town-with-1-trillion-of-ai-capex?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Dan Ives Expects &#8216;Drop The Mic Performance&#8217; Tomorrow From Nvidia: Here&#8217;s Why</a>
Arcese remarked on the unusual combination of factors like GDP growth, earnings growth, and&nbsp;falling inflation and interest rates, which he described as rare. He noted that while utilities are more expensive than before, they remain less costly than the broader market, with growth driven by increased electricity demand from data centers and AI advancements.
Why It Matters: The concerns raised by Arcese align with recent warnings from other financial experts.&nbsp;David Einhorn, founder of Greenlight Capital<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42087680/billionaire-investor-david-einhorn-calls-it-most-expensive-market-of-all-time-as-sp-500-gains-4-since-trumps-win-really-really-pricey">, recently labeled the current market</a> as &#8220;the most expensive of all time,&#8221; citing the high Shiller cyclically adjusted price-to-earnings ratio.
Similarly,&nbsp;Stifel&#8217;s&nbsp;Barry Bannister predicted a <a href="https://www.benzinga.com/markets/equities/24/09/40974512/stifel-warns-of-12-market-drop-by-end-of-2024-as-s-p-500-faces-high-valuations-and-speculative-r">12% market drop</a> by the end of 2024, driven by high valuations and speculative risks. The S&amp;P 500&#8217;s price-to-earnings multiple is nearing historic highs, reminiscent of previous market peaks.
Despite these concerns,&nbsp;<a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42024472/goldman-sachs-us-to-dominate-2025-growth-with-2-5-gdp-boost-euro-area-will-struggle">Goldman Sachs&nbsp;forecasts </a>strong U.S. economic growth in 2025, with a 2.5% GDP boost, suggesting potential resilience in the face of current market challenges.
Price Action: As of Friday, according to <a href="https://pro.benzinga.com">Benzinga Pro</a>, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) that tracks the S&amp;P 500 closely witnessed a 25.60% increase in its year-to-date (YTD) returns while Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) saw a hike of 25.43%. However, during pre-market hours on Friday, both the ETFs were trading slightly lower.
On Friday, <a href="https://www.benzinga.com/24/11/42133364/us-stocks-on-edge-but-likely-to-end-the-week-in-the-green-trumps-treasury-pick-in-focus-expert-says-case-for-fed-pause-in-december-getting-stronger">futures show a decline across major indices</a>: Nasdaq 100 down 0.51%, S&amp;P 500 down 0.40%, Dow Jones down 0.29%, and R2K down 0.08%.
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42082077/if-you-bought-bitcoin-at-387-a-decade-ago-you-would-now-have-more-than-2x-the-average-us-retirement-savings?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">If You Bought Bitcoin At $387 A Decade Ago, You Would Now Have More Than 2X The Average US Retirement Savings</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Analyst Color

Potential 'Healthy Correction' For An 'Expensive' Market Looms As US Economic Growth And Earnings Slow, Says Asset Manager: S&P 500, Nasdaq Futures Trade Lower In Premarket

KBR Inks Pact With AMUFERT For The Development Of A New Ammonia Plant In Soyo, Angola

The company said its subsidiary Beneficient Company Holdings, L.P. consummated a previously announced transaction pursuant to which approximately $35 million of its preferred equity was redesignated as non-redeemable, resulting in the addition of approximately $35 million of permanent equity on its balance sheet.&nbsp;

BENF

Beneficient Says It Believes It Now Has Stockholders' Equity Of At Least $2.5M, The Amount Required To Regain Compliance With Nasdaq's Minimum Stockholders' Equity Requirement

SCLX

Scilex Holding Company Announces Receipt Of Notice From Nasdaq For Its Failure To File Its Quarterly Report On Form 10-Q For The Quarter Ended September 30

Needham analyst Tom Nikic initiates coverage on Skechers USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) with a Hold rating.

Initiation

Needham Initiates Coverage On Skechers USA with Hold Rating

This milestone follows Tri Pointe Homes' entry into the greater Orlando market, a strategic expansion driven by the area's robust growth and demand for high-quality housing options.

Tri Pointe Homes Says It Closed On First Land Acquisition In The Greater Orlando Market, Marking The Homebuilder's Debut In Minneola's Sugarloaf Mountain Community

Needham analyst Tom Nikic initiates coverage on Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Hold rating.

LULU

Needham Initiates Coverage On Lululemon Athletica with Hold Rating

Needham analyst Tom Nikic initiates coverage on Crocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) with a Buy rating and announces Price Target of $116.

CROX

Needham Initiates Coverage On Crocs with Buy Rating, Announces Price Target of $116

Needham analyst Tom Nikic initiates coverage on Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) with a Hold rating.

SHOO

Needham Initiates Coverage On Steven Madden with Hold Rating

Monopar stock climbs as it takes over Wilson disease drug candidate

Monopar Therapeutics (MNPR) announced that it intends to offer to sell shares of its common stock in a best efforts public offering. All of the sha...

Monopar Therapeutics announces common stock offering, no amount given

Monopar Therapeutics proposes public offering of common stock

Monopar Therapeutics drops 16%, prices $19M offering at $16.25 per share

Rodman & Renshaw acted as sole book running manager for the offering. Published first on TheFly – the ultimate source for real-time, market-moving ...

Monopar Therapeutics 1.16M share Spot Secondary priced at $16.25

Monopar Therapeutics Inc ( ($MNPR) ) just unveiled an announcement. Monopar Therapeutics Inc., a biotech firm focused on innovative treatments, suc...

Monopar Therapeutics Closes $19.2 Million Stock Offering

Cash and cash equivalents as of September 30, 2024, were $6.0 million. As noted above, the Company completed a registered public offering on Octobe...

Monopar Therapeutics reports Q3 EPS (37c), consensus (48c)

Monopar Therapeutics GAAP EPS of -$0.37

JonesResearch raised the firm's price target on Monopar Therapeutics (MNPR) to $37 from $9 and keeps a Buy rating on the shares post the Q3 report....

Monopar Therapeutics price target raised to $37 from $9 at JonesResearch

Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Monopar Therapeutics Inc (MNPR – Research Report). The associated price ta...

Comments

Monopar Therapeutics

Monopar Therapeutics (MNPR) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO